Table 3 Adverse metabolic phenotypes at baseline and the 4YFU
FMT | Placebo | pCMH | |||||
|---|---|---|---|---|---|---|---|
BL | 4YFU | pMcN | BL | 4YFU | pMcN | ||
Obesitya | 26 (100%) | 23 (88%) | - | 28 (100%) | 24 (86%) | - | >0.99 |
High waist circumferencea | 26 (100%) | 23 (88%) | - | 28 (100%) | 26 (93%) | - | 0.66 |
Metabolic syndrome | 9 (35%) | 7 (28%) | 0.72 | 7 (25%) | 12 (43%) | 0.13 | 0.95 |
Dyslipidaemia | 19 (73%) | 16 (64%) | 0.51 | 21 (75%) | 20 (71%) | >0.99 | 0.75 |
Impaired fasting glucose | 8 (31%) | 9 (36%) | >0.99 | 9 (32%) | 7 (25%) | 0.68 | 0.75 |
Hypertension | 7 (27%) | 7 (27%) | >0.99 | 5 (18%) | 10 (36%) | 0.23 | 0.98 |
Abnormal liver function | 9 (35%) | 5 (20%) | 0.34 | 5 (18%) | 6 (21%) | >0.99 | 0.48 |
